Ironwood Pharmaceuticals (IRWD) Interest Expenses (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Interest Expenses across 17 years of filings, most recently posting $9.1 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $9.1 million, up 13.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.8 million (changed 0.17% YoY), and the FY2025 annual result was $32.7 million, down 0.87% from the prior year.
• Interest Expenses came in at $9.1 million for Q1 2026 at Ironwood Pharmaceuticals, up from $7.9 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $9.8 million in Q3 2023 to a low of $1.5 million in Q3 2022.
• The 5-year median for Interest Expenses is $7.9 million (2025), against an average of $6.1 million.
• Across the five-year window, Interest Expenses sank 80.81% in 2022 and jumped 545.6% in 2023, its largest moves.
• Ironwood Pharmaceuticals' Interest Expenses stood at $1.5 million in 2022, then soared by 451.97% to $8.4 million in 2023, then gained by 5.83% to $8.9 million in 2024, then fell by 11.53% to $7.9 million in 2025, then increased by 15.91% to $9.1 million in 2026.
• The last three Interest Expenses figures came in at $9.1 million (Q1 2026), $7.9 million (Q4 2025), and $8.4 million (Q3 2025), per Business Quant data.